

IN THE SPECIFICATION

At page 31, after the last line of text, insert the following:

A2
--The hybridoma identified in this application as MR1 was deposited on May 22, 1992 with the American Type Culture Collection, ATCC, International Depository Authority, 12301 Parklawn Drive, Rockville, Maryland 20852, in compliance with the Budapest Treaty, and accorded Accession Number ATCC HB 11048. All restrictions as to the availability to the public of the hybridoma cell line MR1 will be irrevocably withdrawn upon issuance of a United States Patent to this application. Also, access to the MR1 cell line will be available to the Commissioner during the pendency of this patent application or to one determined by the Commissioner to be entitled to such cell line under 37 C.F.R. §1.14 and 35 U.S.C. §122.--

IN THE CLAIMS

Kindly cancel all of Claims 1 through 41, and substitute the following claims therefor.

Sub (B.1)
A3
Com. t
--42. A method for inhibiting a humoral immune response comprising contacting T-cells with an antibody that binds specifically to a protein specifically recognized by monoclonal antibody MR1 produced by the hybridoma having ATCC Accession No. HB 11048.